Nick Giafis joined Kronos Bio in 2023 as Vice President of Medical Affairs. He is responsible for developing a compelling and integrated strategy that supports clinical development and, ultimately, launch of Kronos Bio’s product portfolio. Mr. Giafis joins the Kronos Bio team from Arcus Biosciences where he successfully built a new global medical affairs organization in support of multiple clinical stage oncology assets. Previously, Mr. Giafis worked at Pharmacyclics, an AbbVie company, where he served as Head of Medical Strategy and Evidence Generation for Imbruvica across its eleven FDA approvals. Prior to his role at Pharmacyclics, he served as Scientific Director in US Medical Affairs at AbbVie, where he led the US launch planning and execution for Venclexta in hematologic malignancies. Before joining AbbVie, Nick led the development and execution of the US and Global Scientific Affairs strategy for Abbott Molecular’s portfolio of oncology diagnostic, prognostic, and predictive tests. Earlier in his career, Mr. Giafis worked as a Senior Medical Science Liaison at Bristol-Myers Squibb. Mr. Giafis holds a Ph.D. in Cancer Biology from Northwestern University, and he completed his B.S. in Cell Biology from the University of Illinois at Urbana-Champaign.